Asarina Pharma AB (publ) (ASRPF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Asarina Pharma AB (publ) (ASRPF) with AI Score 43/100 (Weak). Asarina Pharma AB (publ) is a Swedish biopharmaceutical company focused on developing novel treatments for brain-related conditions, particularly those affecting women. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Asarina Pharma AB (publ) (ASRPF) Healthcare & Pipeline Overview
Asarina Pharma AB (publ) is a biopharmaceutical company specializing in women's health and neurological disorders, focusing on developing innovative treatments for conditions like PMDD. With a market capitalization of $0.04 billion and a P/E ratio of 244.07, the company operates in a competitive biopharmaceutical landscape.
Investment Thesis
Asarina Pharma presents a high-risk, high-reward investment opportunity within the biopharmaceutical sector. The company's focus on women's health and neurological disorders, particularly PMDD, addresses a significant unmet medical need. A successful clinical trial outcome and subsequent regulatory approval for their lead compound could drive substantial value. However, the company's OTC listing and limited financial data necessitate careful due diligence. The current P/E ratio of 244.07 reflects investor expectations of future growth, but also highlights the potential for volatility. Key catalysts include upcoming clinical trial results and potential partnerships. Investors should closely monitor the company's cash runway and ability to secure additional funding.
Based on FMP financials and quantitative analysis
Key Highlights
- Market capitalization of $0.04 billion indicates a small-cap company with potential for growth but also higher risk.
- P/E ratio of 244.07 suggests that the company's stock price is high relative to its earnings, reflecting investor expectations of future growth.
- Profit margin of 11.9% demonstrates the company's ability to generate profit from its revenue, although this may fluctuate due to R&D expenses.
- Gross margin of 44.6% indicates the company's efficiency in managing its cost of goods sold.
- The company's focus on PMDD addresses a significant unmet medical need in women's health.
Competitors & Peers
Strengths
- Novel compounds targeting unmet medical needs.
- Focus on women's health, a growing market.
- Potential for first-mover advantage in PMDD treatment.
- Proprietary technology and intellectual property.
Weaknesses
- Limited financial resources.
- Dependence on a small number of product candidates.
- High risk of clinical trial failure.
- OTC listing indicates lower liquidity and transparency.
Catalysts
- Upcoming: Clinical trial results for lead compound in PMDD patients.
- Ongoing: Potential for strategic partnerships with larger pharmaceutical companies.
- Ongoing: Increasing awareness and diagnosis of PMDD driving demand for treatments.
- Ongoing: Advancements in drug delivery technology improving treatment efficacy.
Risks
- Potential: Clinical trial failure or delays in regulatory approval.
- Potential: Competition from established pharmaceutical companies.
- Ongoing: Limited financial resources and dependence on external funding.
- Ongoing: OTC listing indicates lower liquidity and transparency.
- Potential: Shell Risk Detected indicates potential issues that require thorough investigation.
Growth Opportunities
- Expansion into new markets: Asarina Pharma has the opportunity to expand its geographic reach by seeking regulatory approval and commercializing its products in new markets, such as the United States and Asia. The global market for women's health products is estimated to reach billions of dollars, providing a significant growth opportunity for the company. Timeline: 2-5 years.
- Development of new indications: Asarina Pharma can leverage its existing compounds and expertise to develop treatments for new indications beyond PMDD, such as other neurological disorders. This would diversify the company's product pipeline and reduce its reliance on a single product. The market for neurological disorder treatments is substantial and growing. Timeline: 3-7 years.
- Strategic partnerships: Asarina Pharma can form strategic partnerships with larger pharmaceutical companies to accelerate the development and commercialization of its products. These partnerships can provide access to funding, expertise, and distribution networks. The biopharmaceutical industry is characterized by collaborations and acquisitions. Timeline: Ongoing.
- Advancements in drug delivery: The company can explore innovative drug delivery methods to improve the efficacy and patient compliance of its treatments. This could involve developing new formulations, such as long-acting injectables or transdermal patches. The drug delivery technology market is constantly evolving. Timeline: 2-5 years.
- Increased awareness and diagnosis of PMDD: As awareness and diagnosis of PMDD increase, the demand for effective treatments is expected to grow. Asarina Pharma can capitalize on this trend by educating healthcare providers and patients about the condition and its available treatments. Increased awareness will lead to more patients seeking help. Timeline: Ongoing.
Opportunities
- Expansion into new markets and indications.
- Strategic partnerships with larger pharmaceutical companies.
- Advancements in drug delivery technology.
- Increasing awareness and diagnosis of PMDD.
Threats
- Competition from established pharmaceutical companies.
- Regulatory hurdles and delays.
- Patent expirations.
- Changes in healthcare policy and reimbursement.
Competitive Advantages
- Patented pharmaceutical compounds provide exclusivity.
- Clinical trial data demonstrating efficacy creates a barrier to entry.
- Regulatory approvals grant market exclusivity.
- Specialized expertise in neuropsychopharmacology.
- First-mover advantage in specific niche markets.
About ASRPF
Asarina Pharma AB (publ) is a Swedish biopharmaceutical company dedicated to developing and commercializing innovative treatments for brain-related conditions. Founded with the vision of addressing unmet medical needs in neurological and psychiatric disorders, particularly those affecting women, the company has focused its research and development efforts on novel compounds with unique mechanisms of action. Their lead product candidates are designed to target specific receptors and pathways in the brain to alleviate symptoms and improve the quality of life for patients. The company's primary focus is on developing treatments for premenstrual dysphoric disorder (PMDD), a severe form of premenstrual syndrome (PMS) that affects a significant portion of women of reproductive age. Asarina Pharma's lead compound is being developed as a potential first-line treatment for PMDD, offering a novel approach to managing the condition's debilitating symptoms. In addition to PMDD, Asarina Pharma is also exploring the potential of its compounds in other neurological disorders, including Tourette's syndrome and other conditions characterized by imbalances in brain neurotransmitter systems. Asarina Pharma operates primarily in Europe, with its research and development activities based in Sweden. The company's strategy involves conducting clinical trials to evaluate the safety and efficacy of its product candidates, with the goal of obtaining regulatory approval and commercializing its treatments in key markets worldwide. Asarina Pharma is committed to advancing the field of neuropsychopharmacology and improving the lives of individuals affected by brain-related disorders.
What They Do
- Develop novel treatments for brain-related conditions.
- Focus on women's health, particularly premenstrual dysphoric disorder (PMDD).
- Conduct clinical trials to evaluate the safety and efficacy of their product candidates.
- Seek regulatory approval for their treatments in key markets worldwide.
- Commercialize their treatments through partnerships or direct sales.
- Advance the field of neuropsychopharmacology.
Business Model
- Develop and patent novel pharmaceutical compounds.
- Conduct clinical trials to demonstrate safety and efficacy.
- Seek regulatory approval from agencies like the FDA and EMA.
- Commercialize approved drugs through direct sales or partnerships.
- Generate revenue through drug sales and licensing agreements.
Industry Context
Asarina Pharma operates within the biopharmaceutical industry, which is characterized by high research and development costs, lengthy regulatory approval processes, and intense competition. The market for treatments for women's health conditions, including PMDD, is growing, driven by increasing awareness and demand for effective therapies. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying for market share. Asarina Pharma's success depends on its ability to develop and commercialize innovative treatments that offer advantages over existing therapies.
Key Customers
- Women suffering from premenstrual dysphoric disorder (PMDD).
- Patients with other neurological disorders.
- Healthcare providers who prescribe their medications.
- Pharmacies that dispense their medications.
- Hospitals and clinics that use their treatments.
Financials
Chart & Info
Asarina Pharma AB (publ) (ASRPF) stock price: Price data unavailable
Latest News
No recent news available for ASRPF.
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ASRPF.
Price Targets
Wall Street price target analysis for ASRPF.
MoonshotScore
What does this score mean?
The MoonshotScore rates ASRPF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
ASRPF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Asarina Pharma AB (publ) may not meet the minimum financial or disclosure requirements for higher tiers like OTCQB or OTCQX. Companies in this tier often have limited operating history, minimal assets, and may be subject to greater regulatory scrutiny. Investing in companies on the OTC Other tier carries significant risks compared to those listed on major exchanges like NYSE or NASDAQ, due to less stringent listing standards.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower liquidity can lead to price volatility and difficulty in trading.
- Higher risk of fraud or manipulation compared to listed exchanges.
- Potential for delisting or suspension of trading.
- Shell Risk Detected indicates potential issues that require thorough investigation.
- Verify the company's financial statements and audit reports.
- Research the background and experience of the management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent protection.
- Investigate any regulatory filings or legal proceedings.
- Confirm the company's good standing with relevant authorities.
- Understand the risks associated with investing in OTC stocks.
- Focus on addressing unmet medical needs in women's health.
- Development of novel compounds with unique mechanisms of action.
- Conducting clinical trials to evaluate safety and efficacy.
- Scientific publications or presentations related to their research.
- Established partnerships with reputable organizations (if any).
Common Questions About ASRPF
What does Asarina Pharma AB (publ) do?
Asarina Pharma AB (publ) is a biopharmaceutical company focused on developing novel treatments for brain-related conditions, particularly those affecting women. Their primary focus is on premenstrual dysphoric disorder (PMDD), a severe form of PMS. The company's lead compound is being developed as a potential first-line treatment for PMDD, offering a novel approach to managing the condition's debilitating symptoms. They also explore potential applications in other neurological disorders.
What do analysts say about ASRPF stock?
Due to the company's OTC listing and limited analyst coverage, there is no readily available analyst consensus on ASRPF stock. Investors should conduct their own thorough due diligence, considering the company's financial condition, clinical trial progress, and the risks associated with investing in OTC-listed companies. The P/E ratio of 244.07 suggests high growth expectations, which may or may not be realized.
What are the main risks for ASRPF?
The main risks for Asarina Pharma include the potential for clinical trial failure, competition from established pharmaceutical companies, limited financial resources, and the risks associated with its OTC listing. The "Shell Risk Detected" warning also indicates a potential issue that requires further investigation. Investors should carefully consider these risks before investing in ASRPF, as they could significantly impact the company's future performance.
What are the key factors to evaluate for ASRPF?
Asarina Pharma AB (publ) (ASRPF) currently holds an AI score of 43/100, indicating low score. Key strength: Novel compounds targeting unmet medical needs.. Primary risk to monitor: Potential: Clinical trial failure or delays in regulatory approval.. This is not financial advice.
How frequently does ASRPF data refresh on this page?
ASRPF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ASRPF's recent stock price performance?
Recent price movement in Asarina Pharma AB (publ) (ASRPF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Novel compounds targeting unmet medical needs.. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ASRPF overvalued or undervalued right now?
Determining whether Asarina Pharma AB (publ) (ASRPF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ASRPF?
Before investing in Asarina Pharma AB (publ) (ASRPF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited information available on OTC-listed companies.
- Financial data may not be as reliable as for listed companies.
- AI analysis pending for ASRPF.